{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T00:06:14Z","timestamp":1759017974244,"version":"3.44.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.annder.2020.04.020","type":"journal-article","created":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T08:47:16Z","timestamp":1593506836000},"page":"667-671","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Meningoradiculitis due to varicella zoster virus reactivation in a patient treated with ixekizumab"],"prefix":"10.1016","volume":"147","author":[{"given":"M.","family":"Dubois","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Morel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Tone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Gaboriau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Gautier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Lazrek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Vermersch-Langlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.annder.2020.04.020_bib0125","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","article-title":"The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis","volume":"55","author":"Blauvelt","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.annder.2020.04.020_bib0130","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1002\/eji.201242605","article-title":"Immunity to infection in IL-17-deficient mice and humans","volume":"42","author":"Cypowyj","year":"2012","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.annder.2020.04.020_bib0135","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1111\/bjd.15723","article-title":"Infections from seven clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasis","volume":"177","author":"Papp","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2020.04.020_bib0140","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.jaad.2017.06.153","article-title":"Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3)","volume":"77","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2020.04.020_bib0145","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s13555-016-0102-0","article-title":"Ixekizumab for the treatment of psoriasis: a review of phase III trials","volume":"6","author":"Farahnik","year":"2016","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.annder.2020.04.020_bib0150","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/jdv.15242","article-title":"Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trials","volume":"33","author":"Langley","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2020.04.020_bib0155","doi-asserted-by":"crossref","DOI":"10.3390\/v10110609","article-title":"Clinical features of varicella-zoster virus infection","author":"Kennedy","year":"2018","journal-title":"Viruses"},{"key":"10.1016\/j.annder.2020.04.020_bib0160","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/WCO.0000000000000092","article-title":"Neurological complications of varicella zoster virus reactivation","volume":"27","author":"Nagel","year":"2014","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.annder.2020.04.020_bib0165","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3899\/jrheum.140831","article-title":"Safety and efficacy of open-label subcutaneous ixekizumab treatment for 48 weeks in a phase II study in biologic-naive and TNF-IR patients with rheumatoid arthritis","volume":"43","author":"Genovese","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1016\/j.annder.2020.04.020_bib0170","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.jaad.2014.08.039","article-title":"Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment","volume":"71","author":"Papp","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2020.04.020_bib0175","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/1346-8138.13755","article-title":"Varicella zoster virus meningitis under ustekinumab because of plaque psoriasis","volume":"44","author":"St\u00f6llberger","year":"2017","journal-title":"J Dermatol"},{"key":"10.1016\/j.annder.2020.04.020_bib0180","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1001\/jamadermatol.2014.4956","article-title":"Systemic therapy for psoriasis and the risk of herpes zoster: a 500,000 person-year study","volume":"151","author":"Shalom","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.annder.2020.04.020_bib0185","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1093\/rheumatology\/key182","article-title":"Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2","volume":"57","author":"Genovese","year":"2018","journal-title":"Rheumatol"},{"key":"10.1016\/j.annder.2020.04.020_bib0190","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1080\/09546634.2018.1445193","article-title":"Biological treatment for psoriasis and the risk of herpes zoster: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)","volume":"30","author":"Shalom","year":"2019","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.annder.2020.04.020_bib0195","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/jdv.15288","article-title":"Initial results of ixekizumab efficacy and safety in real-world plaque psoriasis patients: a multicenter retrospective study","volume":"33","author":"Deza","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2020.04.020_bib0200","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1111\/1346-8138.13927","article-title":"Japanese UNCOVER-1 Study Group. Efficacy and safety of ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis: subgroup analysis of a placebo-controlled, phase 3 study (UNCOVER-1)","volume":"44","author":"Imafuku","year":"2017","journal-title":"J Dermatol"},{"key":"10.1016\/j.annder.2020.04.020_bib0205","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/acr.23738","article-title":"Safety of ixekizumab in patients with psoriatic arthritis: results from a pooled analysis of three clinical trials","volume":"71","author":"Mease","year":"2019","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.annder.2020.04.020_bib0210","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/bjd.16736","article-title":"Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis","volume":"179","author":"Ryan","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2020.04.020_bib0215","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3899\/jrheum.170429","article-title":"Efficacy and safety of ixekizumab in patients with active psoriatic arthritis: 52-week results from a Phase III Study (SPIRIT-P1)","volume":"45","author":"van der Heijde","year":"2018","journal-title":"J Rheumatol"},{"key":"10.1016\/j.annder.2020.04.020_bib0220","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1136\/annrheumdis-2019-216102","article-title":"Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis","volume":"79","author":"Li","year":"2020","journal-title":"Ann Rheum Dis"},{"year":"2012","series-title":"Vaccination des personnes immunod\u00e9prim\u00e9es ou aspl\u00e9niques. Recommandations","author":"Launay","key":"10.1016\/j.annder.2020.04.020_bib0225"},{"year":"2016","series-title":"Highlights of prescribing information \u2013 TALTZ (ixekizumab) injection, for subcutaneous use Initial U.S. Approval","key":"10.1016\/j.annder.2020.04.020_bib0230"},{"key":"10.1016\/j.annder.2020.04.020_bib0235","unstructured":"Prise en charge pratique des patients sous s\u00e9cukinumab \u2014\u00a0Conduite \u00e0 tenir en cas de vaccination, 2017. [Available from: http:\/\/www.cri-net.com\/ckfinder\/userfiles\/files\/fiches-pratiques\/secukinumab\/SEC_14_Vaccination.pdf]"},{"key":"10.1016\/j.annder.2020.04.020_bib0240","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.jid.2017.09.021","article-title":"Protection from psoriasis-related thrombosis after inhibition of IL-23 or IL-17A","volume":"138","author":"Li","year":"2018","journal-title":"J Invest Dermatol"}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S015196382030243X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S015196382030243X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T11:09:32Z","timestamp":1758971372000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S015196382030243X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S015196382030243X"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2020.04.020","relation":{},"ISSN":["0151-9638"],"issn-type":[{"type":"print","value":"0151-9638"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Meningoradiculitis due to varicella zoster virus reactivation in a patient treated with ixekizumab","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2020.04.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}